Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma
Open Access
Abstract
We conducted a comprehensive review of the current literature of published data, clinical trials (MEDLINE; ncbi.pubmed.com), congress contributions (asco.org; esmo.org), and active recruiting clinical trains (clinicaltrial.gov) on targeted therapies in cholangiocarcinoma. Palliative treatment regimens were analyzed as well as preoperative and perioperative treatment options. We summarized the current knowledge for each mutation and molecular pathway that is or has been under clinical evaluation and discussed the results on the background of current treatment guidelines. We established and recommended targeted treatment options that already exist for second-line settings, including IDH-, BRAF-, and NTRK-mutated tumors, as well as for FGFR2 fusion, HER2/neu-overexpression, and microsatellite instable tumors. Other options for targeted treatment include EGFR- or VEGF-dependent pathways, which are known to be overexpressed or dysregulated in this cancer type and are currently under clinical investigation. Targeted therapy in CCA is a hallmark of individualized medicine as these therapies aim to specifically block pathways that promote cancer cell growth and survival, leading to tumor shrinkage and improved patient outcomes based on the molecular profile of the tumor.Keywords
This publication has 312 references indexed in Scilit:
- Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract CancerJAMA Oncology, 2023
- Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinomaCancer Medicine, 2023
- Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancerCancer Medicine, 2022
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 MutationJAMA Oncology, 2021
- Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancersCancer, 2020
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract CancerJAMA Oncology, 2020
- A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinomaCancer, 2018
- Surgical resection for Bismuth type IV perihilar cholangiocarcinomaBritish Journal of Surgery, 2017
- Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti‐BIL study)Cancer, 2015
- Bile duct cysts in adultsBritish Journal of Surgery, 2004